share_log

海翔药业(002099.SZ)：公司在制剂端销售不会建设大规模销售团队

Haixiang Pharmaceutical (002099.SZ): The company will not build a large-scale sales team in pharmaceutical-side sales

Gelonghui Finance ·  May 20 21:40

Gelonghui, May 21丨Haixiang Pharmaceutical (002099.SZ) Investor Relations Activity Record Sheet shows that the company will not build a large-scale sales team in pharmaceutical-side sales, and will mainly expand market sales by participating in collection and cooperating with other sales companies. The company successfully won the bid for the ninth batch of voglevosaccharide tablets approved last year. Supply has already begun this year, and sales markets outside of collection are also being developed simultaneously. Pantoprazole sodium enteric tablets, which passed the consistency evaluation last year, are also on sale, and this year's formulation revenue should increase by magnitude. In addition, reglinide tablets are in the supplementation phase, and a total of 5 hypoglycemic and psychotropic formulation products are in various stages such as verification production or BE tests. The company will deepen the integration of formulations and drive the growth of its own APIs.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment